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There is no established treatment for advanced rhabdomyosarcoma (RMS) with metastases at the time of
diagnosis. A 17-year-old male was referred to our hospital because of a right scrotal mass. Computed
tomography showed multiple lung metastases with pleural effusion and retroperitoneal lymph node
metastasis, and bone scintigraphy revealed multiple bone metastases. Right high orchiectomy was
performed and the tumor was diagnosed as paratesticular embryonal RMS. He was treated with a
multimodal therapy including 17 cycles of combination chemotherapy consisting of cyclophosphamide,
vincristine, doxorubicin and dacarbazine (CYVADIC) and achieved a long-term survival of 4 years.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Rhabdomyosarcoma (RMS) is the most common soft tissue
sarcoma in childhood and adolescence.1 It progresses rapidly, and
the prognosis is poor when the patient has metastases at the time
of diagnosis.2
We herein report a case in which a patient with advanced par-
atesticular RMS was treated with a multimodal therapy including
17 cycles of combination chemotherapy consisting of cyclophos-
phamide (CPA), vincristine (VCR), doxorubicin (ADM), and dacar-
bazine (DTIC) (CYVADIC) and survived for 4 years.Case presentation
A 17-year-old male presented to the outpatient clinic of a near-
by hospital with shortness of breath in June 2006. He had a
6 cm 5 cm non-tender, ﬁrm nodular right scrotal mass that he had
ﬁrst noticed 6months earlier. Chest X-rays showed pleural effusion,
and the cytological examination of the pleural effusionwas positive
for cancer cells. Computed tomography and bone scintigraphy
revealed lung, pleura, bone and abdominal lymph node metastasesþ81 4 2996 5210.
Inc. This is an open access article u(Fig. 1). He was referred to our hospital under suspicion of a right
testicular tumor with multiple metastases.
Right high inguinal orchiectomy and exploratory thoracoscopy
were performed. A 6.0  4.0  2.5 cm mass in the paratesticular
region was compressing the right testicle (Fig. 2A). Microsections
revealed a cellular sarcoma with round to spindle-shaped cells
having scanty cytoplasm and high mitotic activity (Fig. 2B). On
immunohistochemistry, the tumor was positive for desmin and
myogenin, and was diagnosed as embryonal RMS. The exploratory
thoracoscopy showed a pleural dissemination, which was patho-
logically conﬁrmed to be metastatic RMS.
After surgery, the patient was given ﬁve cycles of CYVADIC
chemotherapy (CPA 400 mg/m2, VCR 1 mg/m2, ADM 40 mg/m2,
DTIC 200 mg/m2) and complete remission was obtained (Fig. 2C).
Because the tumor recurred in the pleura and paraaortic lymph
node in March 2007, another cycle of CYVADIC chemotherapy was
given. Thereafter, he received a salvage chemotherapy consisting of
CPA 1200 mg/m2, VP-16 100 mg/m2, VCR 1.5 mg/m2, pirarubicin
60 mg/m2, cisplatin 20 mg/m2, ifosfamide 1800 mg/m2 and acti-
nomycin D 20 mg/kg accompanied with peripheral blood stem cell
transplantation at the department of pediatrics, and again, com-
plete remission was obtained. For the prevention of recurrence,
radiotherapy was performed (36 Gy to the right scrotum to para-
aortic region, 10 Gy to the lung) in September 2007. In February
2009, however, he was found to have pleural effusion andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. CT and bone scintigraphy at presentation. CT imaging showed lung, pleura (A, arrows) and abdominal lymph node metastases (B, arrows) and bone scintigraphy revealed
multiple bone metastases (C, arrows).
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chemotherapy were given, and the local recurrence lesions clearly
shrank. In June 2009, three cycles of additional CYVADIC chemo-
therapy were given because of a lung metastasis and in December
2009 another cycle of CYVADIC chemotherapy was given because of
pleural dissemination and mediastinum recurrence. In February
2010 the patient developed obstructive jaundice due to pancreatic
metastasis, and endoscopic retrograde drainage was performed.
Despite another ﬁve cycles of CYVADIC chemotherapy being given,
the tumor progressed, and in July 2010 the patient died because of
the progression of the metastases (Fig. 3).
Discussion
RMS is the most common type of soft tissue sarcoma in the ﬁrst
2 decades of life.1 The Intergroup Rhabdomyosarcoma Study Group
(IRSG) staging system separates patients by site of the primary
tumor, tumor size and the presence or absence of tumor-involved
regional lymph nodes and distant metastases.1 The presence of
metastatic disease is the strongest predictor of clinical outcomes in
patients with RMS. The treatment outcome for patients with distant
metastases at diagnosis is extremely poor.2 Even with aggressive
multimodal treatments only 27% are expected to be event-free 3years after diagnosis, and the overall survival (OS) at 3 years is only
34%.2 Oberlin et al reported that several patient characteristics
contributed signiﬁcantly to poor event-free survival in patients
with metastases: presence of bone metastases, age of 10 years old
or more, and presence of three or more metastatic sites.2 OS at 3
years is also inﬂuenced signiﬁcantly by number of metastatic sites.
When the patient has 4 or more metastatic sites at diagnosis as the
present case, 3 year OS is less than 15%.3
Approximately 15% of children and adolescence with RMS pre-
sent with metastatic disease, and their prognosis has not improved
signiﬁcantly over the last 15 years.3 There is no standard treatment
for high-risk patients. Although a recent clinical trial using ifosfa-
mide, etoposide, vincristine, doxorubicin, cyclophosphamide, iri-
notecan and radiationwas conducted, high-risk patients had a 3 year
OS of 14%.4 In this case, we used a CYVADIC chemotherapy shown to
be effective against soft tissue sarcomas.5 The patient was able to
undergo a total of 17 cycles of CYVADIC chemotherapyand the tumor
growth could be controlled for 4 years so that his quality of life was
maintained (i.e., he was admitted to a university and could study
even during the treatments). Although CYVADIC chemotherapy is
thus considered to be useful against high-risk paratesticular RMS, it
is not a curative regimen. Finding a novel effective therapy against
advanced RMS will require further investigations.
Figure 3. CT at the tumor progression despite CYVADIC chemotherapy. CT revealed that the tumor progressed in February 2010 (A, arrows), shrank after CYVADIC chemotherapy in
April (B, arrows) and again progressed despite additional chemotherapy in July (C, arrows).
Figure 2. Pathological ﬁndings and CT after ﬁve cycles of CYVADIC chemotherapy. Macroscope image of the surgically resected specimen (A). Microscopic examination showed
embryonal rhabdomyosarcoma composed of round to spindle-shaped cells having scanty cytoplasm and high mitotic activity (B). CT showed a complete response after ﬁve cycles of
CYVADIC chemotherapy (C).
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We experienced a case in which treating metastatic para-
testicular RMS with a multimodal therapy including 17 cycles of
CYVADIC chemotherapy resulted in relatively long-term survival.Consent
Written informed consent was obtained from the patient’s fa-
ther for publication of this case report.Conﬂict of interest
We have no conﬂict of interest to declare.References
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